NEUROFIT

NEUROFIT

Paris, France· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

NEUROFIT is a long-established, specialized preclinical CRO focused exclusively on neuroscience, serving the biopharmaceutical industry since 1996. The company leverages over two decades of expertise and a stable core scientific team to provide flexible, client-integrated research services across a wide range of neurological, psychiatric, and inflammatory indications. Its business model is built on offering validated models, scientific guidance, and custom study designs to de-risk and accelerate early-stage drug development programs for its partners.

Alzheimer's diseaseParkinson's diseaseEpilepsyNeuropathic PainPeripheral NeuropathiesDepressionAnxietyPsychosis

Technology Platform

A comprehensive and continuously updated suite of validated in vivo (animal) and in vitro (cell-based) disease models and behavioral tests for central and peripheral nervous system disorders, including neurology, psychiatry, cognition, and inflammation. Platform emphasizes extensive historical validation data and custom adaptation for client programs.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

Growing demand for specialized neuroscience R&D services due to high unmet need and complex biology.
Opportunity to expand service offerings into advanced models like human iPSC-derived systems and digital biomarkers.
Potential for strategic partnerships with biotechs and larger CROs seeking deep neuroscience expertise.

Risk Factors

Revenue dependent on cyclical biopharma R&D spending and client concentration.
Competition from large, full-service CROs and other niche players.
Scientific risk related to the translational value of animal models and potential regulatory shifts in preclinical requirements.

Competitive Landscape

Competes against large, global contract research organizations (CROs) that offer broad preclinical services, and against other smaller, specialized neuroscience CROs. Differentiation is based on deep, focused expertise in neuroscience models, a stable scientific team, and a flexible, client-integrated partnership approach.